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ABSTRAC T
In this study, we have investigated the ability of insulin-like growth factor I (IGF-I) to inhibit HIV long ter-
minal repeat (LTR)-driven gene expression. Using C OS 7 cells cotransfected with tat and an HIV LTR linked
to a chloramphenicol acetyltransferase (C AT) reporter, we observed that physiological levels of IGF-I (10 2 9
M) significantly inhibited C AT expression in a concentration- and time-dependent manner. IGF-I did not in-
hibit C AT expression in C OS 7 cells transfected with pSVC AT, and did not affect C AT expression in the ab-
sence of cotransfection with tat. Transfection of HIV-1 proviral DNA into C OS 7 cells 6 IGF-I resulted in a
significant decrease (p , 0.05) in infectious virion production. Both IGF-I and Ro24-7429 inhibited LTR-dri-
ven C AT expression, while TNF- a -enhanced C AT expression was not affected by IGF-I. On the other hand,
a plasmid encoding parathyroid hormone-related peptide exhibited dramatic additivity of inhibition of C AT
expression in C OS 7 cells. Finally, we show that in Jurkat or U937 cells cotransfected with HIVLTRC AT/tat,
IGF-I significantly inhibited C AT expression. Further, interleukin 4 showed in U937 cells inhibition of C AT
expression that was not additive to IGF-I induced inhibition. Our data demonstrate that IGF-I can specifi-
cally inhibit HIVLTRC AT expression. This inhibition may occur at the level of the tat/TAR interaction. Fi-
nally, this IGF-I effect is seen in target cell lines and similar paths of inhibition may be involved in the vari-
ous cell types employed.
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INTRODUC TION
D ESPIT E IN TEN SIV E IN VESTIG ATIO N , much remains to belearned about the sequence of events leading to develop-
ment of the acquired immunodeficiency virus syndrome (AIDS)
following human immunodeficie ncy virus (HIV) infection. Of
utmost importance is an understanding of how HIV gene ex-
pression is controlled during the viral life cycle. In this regard,
the long terminal repeats (LTRs), present at either end of the
HIV genome, contain the essential cis-acting signals that spec-
ify the start site for RNA transcription and modulate the
amounts of HIV RNA synthesized. 1,2 HIV replication is criti-
cally dependent on two viral regulatory proteins, Tat and Rev,3
and Tat is required early in the viral life cycle to increase the
rate of transcription from the viral LTR.3
Growth hormone (GH) and insulin-like growth factor I (IGF-
I) have been shown to affect functional immune status4±6 and
lean body mass.7±12 In addition, our laboratory has demon-
strated that IGF-I can inhibit HIV replication. 13 Regarding this
latter effect of IGF-I on HIV replication, the mechanism has
not been elucidated. 13 In our continuing efforts to understand
this IGF-I-induced inhibition of HIV replication, we report
herein that IGF-I inhibition of HIV replication is related to 
IGF-I inhibition of LTR-directed gene expression. Using an
HIV LTR chloramphenico l acetyltransferase (CAT) reporter
(HIVLTRCAT), we show that IGF-I inhibited Tat-mediated
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HIVLTRCAT expression while having little effect on basal
(i.e., in the absence of Tat) CAT production. Other factors that
have known inhibitory sites regarding CAT expression have
been studied in combination with IGF-I to uncover the in-
hibitory site(s) for this hormone. We also show that IGF-I can
inhibit production of infectious HIV virions when COS 7 cells
are transfected with complete genomic proviral DNA. Further,
we have found that CAT expression is inhibited by IGF-I 
in traditional target cell lines (e.g., Jurkat cells, a T cell line,
and U937 cells, a promonocytic cell line) transfected with
HIVLTRCAT/tat.
MATERIALS AND M ETHODS
Cell culture
The cells employed in our transfection studies were COS 7
cells, Jurkat cells, and U937 cells. COS 7 cells were grown in
Dulbecco’ s modified Eagle’ s medium (DMEM) (containing
10% [v/v] fetal calf serum, penicillin [100 U/ml], streptomycin
[100 m g/ml], and 1% [w/v] L-glutam ine). Jurkat and U937 cells
were grown in RPMI 1640 (containing 10% [v/v] fetal calf
serum , penicillin [100 U/ml], streptomycin [100 m g/ml], gluta-
mine [2 mM], pyruvate [1 mM], and HEPES [10 mM]). Cells
were used for experiments when cell densities reached 1 3 106
cells/ml.
Materials
Functional studies of the HIV promoter have been conducted
primarily through experiments in which the HIV LTR has been
linked to a reporter gene, i.e., the bacterial cat gene.14 An
HIVLTRCAT construct and a pSV tat construct were kindly
provided by J. Hiscott (Lady Davis Institute, Montreal, Que-
bec, Canada). IGF-I was kindly supplied by Genentech (San
Francisco, CA).
Transfections
For COS 7 transfections, a standard calcium phosphate pre-
cipitation procedure was employed.14a In short, COS 7 cells
were plated in 10% (v/v) DMEM to yield approximately 30%
confluence after 24 hr. At this time, the medium was changed
to 1% (v/v) DMEM and incubated for 2 hr at 37°C. DNA was
adjusted to 15 m g/plate with calf thymus DNA prepared in
deionized water and 0.25 M CaCl2 in a volume of 0.5 ml. Air
was bubbled into 0.5 ml of 2 3 HEPES buffer (280 mM NaCl,
50 mM HEPES, and 1.5 mM Na2HPO4 ?  7H2O) while simul-
taneously, slowly dripping the DNA mixture into the HEPES
solution. Bubbling was continued until the solution was slightly
cloudy due to CaPO4±DNA precipitation. After allowing the
solution to sit at room temperature to achieve maximum pre-
cipitation, the DNA±HEPES solution was added to the plates
and incubated at 37°C for 4 hr. At this time, the plates were
washed twice with phosphate-buffered  saline (PBS)
(Ca2 1 /Mg2 1 free) and treated as required. For Jurkat cells, the
DEAE-dextran method was employed.15 Briefly, 6 3 106 to
10 3 106 cells per transfection were washed with Tris-buffered
saline (TS) containing 100 m g/ml each of CaCl2 and MgCl2,
resuspended in DNA (5±7 m g) in TS, Tris-EDTA (TE), and
DEAE-dextran (0.46 m M), and incubated for 90 min at 37°C.
Dimethylsulfox ide (DMSO; 10%, v/v) was added for 3 min,
immediately diluted with TS buffer, and centrifuged  at 1000 3
g. Cells were washed twice with PBS (Ca2 1 /Mg2 1 free), re-
suspended in appropriate  medium , and transferred to 25-cm 2
culture flasks. For U937 cells, an electropora tion method was
employed. Cells were transfected at a density of 2 3 107
cells/ml of Opti-MEM (GIBCO, Grand Island, NY) phenol
red-free, serum-redu ced (1%, v/v) medium. The appropriate
DNA (i.e., 10 m g) was added to the cell suspension and the
cells were aliquoted to 0.4-cm electrode gap Gene Pulser cu-
vettes (Bio-Rad, Hercules, CA). Cells were then pulsed at 950
m F and 250 mV using the Bio-Rad Gene Pulser II system with
capacitance  Extender II. After transfection , the cells were
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FIG. 1. The effect of anti-IGF-I receptor antibody ( a IR3) on the inhibition of HIV-1 production in chronically HIV-infected
U937 cells. U937 cells were . 95% positive for HIV. Culture medium reverse transcriptase activity in control U937 HIV-infected
cells was 385 3 10 2 3 cpm/50 m l of culture medium, whereas in the a IR3 control group the reverse transcriptase activity was
325 3 10 2 3 cpm/50 m l of culture medium. The data points represent the average percent inhibition after 24 hr of exposure to
IGF-I or to IGF-I plus a -IR3, 6 SEM. *p , 0.05: control versus IGF-I, IGF-I versus a -IR3, IGF-I versus IGF-I plus a -IR3; one-
way ANOVA; n 5 4 experim ents.
transferred to T-25 (25-cm 2 surface area) flasks containing
medium with 1% (v/v) fetal calf serum plus or minus the de-
sired modulator. In all COS 7 transfectio ns, a cytomegalo virus
(CMV) b -galactosida se was employed as an internal trans-
fection control.
CAT analysis
At varying times following transection, cells were harvested
and washed in 4°C PBS. Cells were then washed in TEN buffer
(40 mM Tris [pH 7.5], 1 mM EDTA [pH 8.0], 15 nM NaCl).
Cell lysates (i.e., the supernatants) were collected and analyzed
for [1,2-14C]chloramphenicol (ICN, Costa Mesa, CA) metabo-
lites. The samples were extracted with ethyl acetate spotted on
thin-layer chromatography (TLC) silica gel membranes (What-
man, Clifton, NJ) and run with a chloroform±methanol (95:5)
eluant. TLC autoradiograms were produced from the TLC mem-
branes following exposure to autoradiography film (Du Pont,
Wilmington, DE). When possible, all CAT assays with low
( , 1%) or high ( . 70%) acetylation were repeated with more or
less extract. The amount of protein and time of incubation at 37°C
were adjusted for degree of acetylation. Quantitation of different
acetylated metabolites of [14C]chloramphenicol was done using
phosphorimage analysis of the patterns produced after the TLC
was exposed to a Bio-Rad GS 250 screen BI for varying amounts
of time and visualized using the Bio-Rad GS-363 Molecular Im-
ager system. Analysis was performed using Bio-Rad Molecular
Analyst software (version 2.0.1).
Reverse transcriptase assay
Reverse transcriptase assays were carried out by a modifi-
cation of a previously published procedure. 3 ,16
Detection of p24 antigen by enzyme immunoassay
Virus production was monitored by detection of p24 core
antigen in cell-free culture supernatants, using an enzyme im-
munoassay (EIA) diagnostic kit (Abbott Laboratories, Missis-
sauga, Ontario, Canada).
Statistics
The statistical analyses employed herein include the two-
tailed t test and one-way analysis of variance (ANOVA). The
lowest level of significance was set at p , 0.05.
RESULTS
An initial series of experiments was performed that recon-
firmed that exposure to IGF-I caused a significant decrease in
culture medium reverse transcriptase (RT) activity produced by
chronically HIV-1-infected  U937 cells (i.e., with the laboratory
strain HIV-IIIB) (Fig. 1). Nearly 40% inhibition of medium RT
activity was seen after 24 hr of exposure to IGF-I (100 ng/ml)
(p , 0.05, one-way ANOVA, n 5 4). Further, the 40% inhibi-
tion of HIV replication by IGF-I was abrogated by a -IR3, a
specific antibody to the IGF-I receptor. 17 In addition, an anti-
IGF-I antibody blocked the IGF-I effect on HIV replication
(data not shown).
To gain some insight into the mechanism of action of IGF-
I on HIV replication, COS 7 cells were cotransfected for 4 hr
with HIVLTRCAT/tat (1 m g of each plasmid per milliliter)
made up to 10 m g/ml with carrier calf thymus DNA. After the
calcium phosphate±DNA mixture was removed, the cells were
treated with IGF-I in DMEM containing 1% (v/v) fetal calf
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FIG. 2. The effect of IGF-I on HIVLTR-driven CAT ex-
pression in COS 7 cells. Cells were transfected with HIVL-
TRCAT and pSV tat as described in Materials and Methods.
Chlorampheni col metabolism represents the sum of the 1-
acetyl and 3-acetyl metabolites generated as a percentage of
the total chloramphenico l spotted [see numbers in parentheses
above each lane in (A)]. Internal transfection controls using b -
galactosidase were determined for control and IGF-I treated
samples. The b -Gal-specific activities (e.g., D OD 3 10 2 3/20
min) for the HIVLTRCAT/tat control duplicates were 1.21 and
1.27; for the 10-ng IGF-I-treated duplicates they were 1.20 and
1.09; and for the 50-ng IGF-I-treated duplicates they were 0.83
and 0.41. (A) TLC chromatogram  depicting the [14C]chloram-
phenicol metabolites (samples in duplicate). Arrows indicate
the metabolite produced: U, unacetylated; 1, 1-acetyl metabo-
lite; 3, 3-acetyl metabolite. (B) The percent inhibition is plot-
ted versus treatment and was quantitated by phosphoimage
analysis of the spots generated. The colum ns represent an av-
erage of the two spots aligned directly above. Liquid scintilla-
tion counting of the spots produced identical patterns when
compared with the phosphoimage patterns. Data are presented
as means 6 SEM.
A
B
serum. After 48 hr, the monolayers were extracted and CAT
activity was determined. The data in Fig. 2A and B demonstrate
a concentration-dep endent inhibition of CAT activity by IGF-
I (77% inhibition at 10 ng/ml [1.3 nM] and 94% inhibition at
50 ng/ml [6.5 nM] IGF-I). A modest 29% inhibition of CAT
expression by a pharmacologic amount (i.e., 500 mU/ml) of in-
sulin has been seen (data not shown). In an earlier study,13 we
demonstrated that physiological concentrations of IGF-I18 (i.e.,
50±100 ng/ml) could inhibit HIV-1 replication in cord blood
mononuclear cells and chronically infected U937 cells. In this
study, we have shown that COS 7 cells cotransfected with the
HIV LTR linked to a cat reporter and tat express high levels
of CAT and that physiologic concentrations 18 of IGF-I signif-
icantly inhibit CAT expression (Fig. 3).
To determine if the effect of IGF-I was specific for the HIV
LTR promoter, we tested the effect of IGF-I on CAT activity
in COS 7 cells transfected with a pSVCAT construct. In Table
1, it can be seen that IGF-I had little effect on CAT activity
(i.e., 100 ng of IGF-I per milliliter resulted in an average CAT
activity of 105%) derived from cells transfected  with pSV-
CAT (p . 0.05, n 5 4). CAT expression,  however, in HIVL-
TRCAT/tat-transfec ted cells, was inhibited 48% at 50 ng of
IGF-I per milliliter (p , 0.05, n 5 4). The differences  seen in
the levels of inhibition of CAT expression (Fig. 2 versus Table
1) represent the inherent variability normally seen in both bi-
ological and transfection  studies. Further, transfection  with
HIVLTRCAT but no tat resulted in considerabl y reduced CAT
expression ( , 7% of HIVLTRCAT/tat expression)  that was
not affected by IGF-I (p . 0.05, n 5 4). Also, we have not
seen any effect of IGF-I on another promoter, using COS 7
cells transfected  with a plasm id containing a phosphogly cer-
ate kinase promoter linked to a luciferase reporter (data not
shown). In Fig. 4, it can be seen that the effect of IGF-I on
CAT activity was time dependent, demonstra ting a maximal
effect ( , 48% inhibition) by 48±72 hr and decreasing by 96
hr to no inhibition. In this latter type of experiment , the IGF-
I concentrati on employed was 100 ng/ml but no additional
IGF-I was added during the course of the experimen t. There-
fore, it is likely that the IGF-I in the medium  has been de-
pleted after 4 days into the experim ent. Based on 6-hr half-
life of IGF-I in the medium , less than 0.02 ng of IGF-I per
milliliter would be left in the medium after 72 hr. In fact, data
obtained when adding fresh IGF-I daily during the experim ent
shows that the inhibitory effect is maintained for more than 4
days (data not shown).
Transfection of COS 7 cells with a plasmid containing the
complete HIV proviral DNA (strain BH10), followed by the ad-
dition of IGF-I (50 ng/ml), resulted in 35% inhibition of infec-
tious viral particle production (Table 2; p , 0.001, n 5 4). This
is suggestive of IGF-I inhibiting HIV replication postintegra-
tion (i.e., provirus activation).
To characterize further this effect of IGF-I on HIV LTR-dri-
ven CAT expression, we employed the Roche Tat inhibitor
Ro24-7429 19 alone and in combination with IGF-I (Table 3).
The data in Table 3 show that the inhibition of CAT expres-
sion by IGF-I alone was , 40%, while the inhibition seen with
Ro24-7429 at 10 2 8 and 10 2 7 M was 55 and 63%, respectively.
IGF-I, in combination with 10 2 8 or 10 2 7 M Ro24-7429, in-
hibited CAT expression 57 and 55%, respectively. Since Ro24-
7429 is a specific Tat inhibitor 19 and there was no additive ef-
fect of the two inhibitors, it would suggest that IGF-I might
affect the Tat±TAR (trans-activation response element) com-
plex interaction or Tat interactions with other proteins. Tumor
necrosis factor a (10 ng/ml), which can enhance CAT expres-
sion, was not affected by IGF-I in this transfection system (data
not shown).
GERM INAR IO ET AL.832
FIG. 3. The effect of increasing concentrations of IGF-I on HIVLTRCAT expression in cotransfected COS 7 cells. Percent in-
hibition is plotted against increasing concentrations of IGF-I. Cells were transfected with tat and HIVLTRCAT and CAT activ-
ity was assayed 48 hr later as described in Materials and Methods. The data represent the average percent inhibition 6 SEM.*p ,
0.05: one-way ANOVA; n 5 3±5 experiments.
A parathyroid hormone-related  peptide (PTHRP) plasm id,
minus the signaling sequence, has been reported to share sim-
ilarities with the nuclear localization signal of Tat.20 Therefore,
we questioned whether PTHRP might affect Tat activation of
HIVLTRCAT by competing with Tat for nuclear entry, and
whether PTHRP could affect the inhibition of CAT expression
by IGF-I. This latter finding might indicate a site for IGF-I-in-
duced inhibition (i.e., competition at the level of nuclear entry).
The data in Table 4 indicate that PTHRP yielded 27% inhibi-
tion of CAT plus Tat expression when compared with controls
(i.e., CAT plus Tat with no PTHRP). IGF-I resulted in a 60%
decrease in CAT plus Tat expression. In combination, PTHRP
and IGF-I inhibited CAT expression 88%. This indicated an ad-
ditivity of effects that would suggest that IGF-I is not inhibit-
ing CAT expression at the level of Tat nuclear localization.
The observation that IGF-I can inhibit CAT expression and
HIV replication in COS 7 cells, a nontarget cell for HIV, led
us to investigate the effect of IGF-I in a T cell line (Jurkat) and
in the promonocytic cell line U937. Cotransfection of Jurkat
cells with HIVLTRCAT/tat, and subsequent exposure to IGF-
I (50 ng/ml), resulted in a significant inhibition of CAT ex-
pression, i.e., 63% (Table 5) (p , 0.05, n 5 10). In experiments
employing a Jurkat cell line stably transfected with tat, CAT
expression posttransfection with HIVLTRCAT was inhibited
32% by IGF-I (data not shown). Similarly, the effect of IGF-I
on CAT expression in cotransfected U937 cells (Table 5)
yielded a significant (i.e., 58%) inhibition of CAT expression
(p , 0.05, one-way ANOVA, n 5 7). Of considerable interest
is the fact that interleukin 4 (IL-4), the signaling pathway of
which is similar to that of IGF-I (i.e., via IRS-1 and IRS-2),21±24
also significantly inhibited CAT expression (p , 0.05, one-way
ANOVA, n 5 7). Further, the combination of IGF-I and IL-4
showed no significant additive inhibition (e.g., IGF-I versus IL-
4 plus IGF-I; IL-4 versus IGF-I plus IL-4; p . 0.05). The pre-
ceding inform ation supports the thesis that common pathways
are employed by both factors to inhibit HIVLTRCAT expres-
sion. The cell lines employed in this study all possessed IGF-I
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TA BL E 1. SPEC IFIC IT Y OF IGF-I EFFEC T ON CAT EXPRE SSIO Na
Chlorampheni col metabolism
Transfection conditions (units/mg protein/unit b -galactosidase)
Cat 1 IGF-1
tat promoter 2 IGF-I (100 ng/ml) Percentage of control
2 pSV 19,909 6  6,630 20,889 6  4,651b  105
1 HIV LTR 105,051 6  12,030 54,239 6  14,195 c 52
2 HIV LTR 7,458 6  1,885 7,091 6  1,122b 95
aCOS 7 cells were transfected as described in Materials and Methods. Analysis was perform ed on lysates obtained 48 hr 
posttransfection. Conversion of chloramphenico l to its respective metabolites ranged from 10 to 42%. All data are presented as
means 6 SEM.
bp . 0.05, no significant difference from control, two-tailed t test, n 5 4.
cp , 0.05, significant difference from control, two-tailed t test, n 5 4.
TABLE 2. EFFEC T O F IGF-I ON HIV-1 INFEC TIO US VIR IO N
PRO DUCTIO N BY TRAN SFEC TED COS 7 CELLS a
p24 antigen
Treatment (pg/ml)
Control 20,515 6  3,961b
1 IGF-I (50 ng/ml) 14,188 6  3,792b
aCells were transfected as described in Materials and 
Methods, with several changes. Complete viral genomic
DNA(BH10)±CaPO4 was left on the cells overnight before 
removal, follow ed by IGF-I addition, and virus production was
monitored after 4 days. Data are presented as means 6 SEM.
bp , 0.001, significant difference from control, two-tailed 
t test, n 5 4.
FIG. 4. The effect of time of exposure to IGF-I on HIVL-
TRCAT expression in COS 7 cells cotransfected with tat (pSV
tat). All conditions were as described in Materials and Meth-
ods. The IGF-I concentration was 100 ng/ml and time 0 refers
to IGF-I addition posttransfection. The data represent the aver-
age percent inhibition 6 SEM. *p , 0.05; one-way ANOVA;
n 5 3 or 4 experim ents.
receptors, as indicated by the amount of specific binding de-
termined for each cell line (Table 6). COS 7 and U937 cells
both had significantly higher IGF-I binding than did Jurkat cells
(p , 0.01, one-way ANOVA: COS 7, n 5 12; Jurkat, n 5 16;
U937, n 5 6).
DISC USSION
In this article, we have demonstrated clearly that IGF-I can
inhibit the functioning of the HIV LTR. Using a CAT-linked
reporter, we show that Tat-amplified HIVLTRCAT expression
is significantly inhibited in a concentration- and time-depen-
dent manner by physiological levels of IGF-I18 (Fig. 2A and B;
and Fig. 3). In addition, IGF-I did not affect the expression of
a pSVCAT-linked reporter at concentrations that affected
HIVLTRCAT expression (Table 1). This effect of IGF-I was
seen on the production of infectious virions by COS 7 cells
transfected with proviral HIV DNA (Table 2), which is sug-
gestive of IGF-I inhibiting HIV at a postintegration step. As a
further attempt to localize the site(s) of IGF-I inhibition, we in-
vestigated the importance of Tat in this IGF-I inhibitory effect.
Data obtained on the effect of IGF-I on CAT expression in the
absence of Tat amplification indicated that basal CAT expres-
sion in COS 7 cells was not affected by IGF-I (Table 1). Our
data with the specific Tat inhibitor Ro24-7429 19 and IGF-I in-
dicated that similar inhibitory paths are involved. On the other
hand, expression from a transfected plasmid of PTHRP, which
has a nuclear localization signal similar to that of Tat,20 showed
inhibition that was additive to that obtained with IGF-I alone
(Table 4). This would suggest that different inhibitory paths
were being employed.
The possibility that IGF-I can possibly interact with the
Tat±TAR complex or some protein affecting this complex is
not difficult to accept. Tat does not act alone. In addition to
binding the trans-action response element (TAR), Tat must in-
teract directly or indirectly with the transcription apparatus.
Several reports have indicated a role for upstream enhancers in
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TA BLE 3. EFFECT OF Tat IN HIB ITO R Ro 24-7429 IN COM BINA TIO N W ITH
IGF-I O N EXPRESSIO N OF CAT IN TRANSFEC TED COS 7 CEL LSa
Treatment Chloramphenicol metabolism
48 (hr) (units 3 10 2 3/mg protein/unit b -galactosidase)
Control 9811 6 1105
1 IGF-I (50 ng/ml) 6100 6  1093
1 10 2 8 M Ro24-7429 4423 6  885b
1 10 2 7 M Ro24-7429 3508 6  903b
IGF-I (50 ng/ml) 1 4246 6  911b
10 2 8 M Ro24-7429
IGF-I (50 ng/ml) 1 4512 6  755b
10 2 7 M Ro24-7429
aCells were transfected as described in Materials and Methods. Analysis of CAT
was performed on cell lysates 48 hr after transfection. Metabolic conversion of 
chloramphenico l to its respective metabolites ranged from 10 to 45%. Quantitation
was by phosphoimage analysis. Data are presented as means 6 SEM.
bSignificantly different from control; p , 0.05, one-way ANOVA.
TABLE 4. EFFEC T OF PARAT HYROID HORM O NE-RELA TE D PEP TID E IN COM BINA TIO N W ITH IGF-I 
O N Tat-MED IATE D trans-ACT IVAT ION OF HIVLTRCAT EX PRES SION IN COS 7 CEL LSa
Transfection Chloramphenic ol metabolism
conditions Treatment (units/mg protein/unit b -galactosidase)
Calf thymus DNA None 3,970 6  294
HIVLTRCAT/tat None 243,937 6  36,307
HIVLTRCAT/PTHRP None 5,542 6  1,593
HIVLTRCAT/tat 1 IGF-I (50 ng/ml) 99,541 6  15,082 b
HIVLTRCAT/tat/PTHRP None 117,516 6  26,897 b
HIVLTRCAT/tat/PTHRP 1 IGF-I (50 ng/ml) 41,634 6  5,035b
aAll conditions as in Materials and Methods. Briefly, COS 7 cells were transfected for 4 hr with HIVLTRCAT, tat, and/or
PTHRP. IGF-I was added after 4 hr and CAT activity was determined after 48 hr. Quantitation was by phosphoimage analysis.
Metabolic conversion of chloramphenicol to its respective metabolites ranged from 3 to 64%. All data are presented as 
means 6 SEM (n 5 2).
bSignificantly different from HIVLTRCAT/tat: p , 0.05, one-way ANOVA.
Tat trans-activation. 25±27 The HIV LTR contains an enhancer
region consisting of NF-k B and three Sp1-binding sites,26 ,27 al-
though a fourth Sp1 site has been identified. 28 Interestingly, 
different enhancer elements have different efficiencies in con-
ferring Tat responsiveness, with Sp1 sites being most effec-
tive.25,29 This is to be noted since the pSVCAT construct con-
tains an Sp1 site and is not affected by IGF-I (Table 1). This
does not necessarily exclude the involvement of the Sp1 sites
in the HIV LTR for several reasons: (1) the Sp1 sites in the
HIV LTR are not functionally equivalent; 30 (2) the architecture
of the Sp1 site in the pSVCAT construct is physically differ-
ent from that in the HIVLTRCAT construct; and (3) LTRs show
different effects with respect to enhancer activation, depending
on the cell type and differentiation state of the cell.31,32 This
could relate to the number of host cell factors that are involved
in Tat-mediated effects, e.g., it has been reported that human
chromosome 12 encodes a factor that can potentiate Tat trans-
activation in rodent cells.33 Further, a number of candidate cel-
lular proteins may play a role in Tat trans-activation. 2 All this
notwithstanding , one report has demonstrated that IGF-I can
disrupt Sp1 binding of the elastin gene in smooth muscle cells,
possibly through the modulation of the phosphorylation state of
the retinoblastom a gene product, RB.34 How the preceding re-
lates to the mechanism of Tat-mediated trans-activation, if at
all, supports the notion that the Tat±TAR interaction is com-
plex and controversial.
Few studies have investigated the effects of growth hormone
and/or IGF-I35 and insulin on HIV replication and HIV LTR-
directed gene expression. 3 In the first study, no effect of growth
hormone on HIV replication was observed, most likely owing
to undetectable amounts of IGF-I produced (M.E. Geffner, per-
sonal communication, 1997). In the second study, the investi-
gators used micromolar amounts of insulin, which represents
supraphysiologic concentrations that are not relevant in vivo.36
Further, no mention was made as to whether the results ob-
tained were corrected for protein content of the cell extract or
whether corrections were made for transfection efficiency. In
addition, the conditions employed differed considerably from
those used in this study. Finally, one report37 indicated that their
data did not reliably demonstrate IGF-I inhibition of HIV repli-
cation.13 In their study, similar protocols were employed; how-
ever, the conditions of infection, such as the multiplicity of in-
fection, virus preparations employed, infection procedures used,
and source of IGF-I, may be related to this apparent discrep-
ancy. However, our CAT expression data on the HIV LTR, re-
ported herein, support the observation that was made initially
by our laboratory, 13 showing that IGF-I inhibits HIV-1 repli-
cation.
Of considerable interest regarding the effect of IGF-I on
HIVLTRCAT expression is that these IGF-I inhibitory effects
have been observed in traditional target cell lines such as Jur-
kat and U937. These effects of IGF-I were seen at physiologi-
cal concentrations of IGF-I18 and further support the thesis that
this molecule is relevant in HIV replication. Also, we have seen
that IL-4 can inhibit HIVLTRCAT expression (Table 5) in
transfected U937 cells. This inhibition by IGF-I and IL-4 was
not additive (Table 5). We believe that these effects in target
cell types reflect the ability of IGF-I and IL-4 to share common
intracellular signaling pathways. 23,24 In an earlier report, we
had hypothesized that IGF-I might be affecting HIV replication
via the IL-4 pathway.13 Since the main signal transducer for IL-
4 is IRS-2, which is a major signal transducer for insulin/IGF-
I,21,24 IGF-I may affect the IRS-2 pathway and eventually HIV
LTR-driven gene expression. This should be fertile ground for
future investigation.
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TABLE 5. EFFEC T O F IGF-I ON CAT EXPRESSION
IN TRA NSFECTE D TARGE T CELLS a
Chlorampheni col metabolism
Treatment
(units 3 10 2 3/mg protein)
(48 hr) Jurkat cells U937 cells
Control 806.5 6  292b 842 6  120c
1 IGF-I (50 ng/ml) 302.0 6  100b 356 6  58c,d
1 IL-4 (10ng/ml) Not done 235 6  47c,d
IL-4 1  IGF-I Not done 55 6  40c,d
aJurkat and U937 cells were transfected as described in 
Materials and Methods. Analysis for CAT activity was per-
formed on cell lysates obtained 48 hr posttransfection. Chlo-
ramphenicol conversion to its respective metabolites ranged
from 14 to 64% for Jurkat cells and from 20 to 60% for U937
cells. All data are presented as means 6 SEM.
bp , 0.05; significant difference from control, two-tailed 
t test, n 5 10.
cp , 0.05; significant difference from control, one-way
ANOVA, n 5 7.
dIGF-I versus IL-4, IGF-I versus IL-4 plus IGF-I, IL-4 ver-
sus IGF-I plus IL-4, p . 0.05.
TABLE 6. SPECIFIC BIND ING OF 25I-LABELED
IGF-I BY COS 7, JURKAT , AN D U937 CELLS a
Specific IGF-I binding
Cell line (fmol/mg protein)
COS 7 5.6 6  0.8b,c (n 5  12)
Jurkat 2.04 6  0.3 (n 5  16)
U937 5.97 6  1.0b,c (n 5  6)
aIGF-I binding was determined on COS 7 confluent 
monolayers and on cell suspensions of Jurkat and U937 cells
at 2 3 106 cells/ml of Hanks’  balanced salt solution with 
25 mM HEPES buffer (pH 7.4) containing 0.2% bovine serum
albumin. Specific binding was determined by the difference 
between the total binding of 125-labeled IGF-I (0.4 ng/ml) and
the total binding of 125I-labeled IGF-I (0.4 ng/ml) in the 
presence of 300 ng of unlabeled IGF-I per milliliter (nonspe-
cific binding). The percent specific binding for each cell line
was as follows: COS 7, 39.6 6 2%; U937, 49 6 5.2%; and 
Jurkat, 30.5 6 3.2%. Different batches of labeled IGF-I were
prepared using chloramine T and had specific activities 
ranging from 160 to 196 m Ci/ m g. Samples were counted on an
LKB Compugamma at an efficiency of 63%. All data are 
presented as means 6 SEM (n 5 2).
bp , 0.01, significant difference from Jurkat cells.
cp . 0.05, no significant difference: COS 7 versus U937 cells.
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